English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A clinical examination and ultrasonograph of an eight year old gelding revealed tendinopathy of a superficial digital flexor tendon (SDFT) after an injury in a cross-country race. The horse was treated using ex vivo -expanded autologous mesenchymal stem cells (MSCs) derived from bone marrow because of their immunoregulatory properties and their ability to heal cartilage and tendon under specific inflammatory conditions, such as trauma. The first application of MSCs into the lesion was performed on day 37 after the injury, and the second one on day 60. After the treatment with MSCs, the tissue of the injured tendon was nearly completely healed on day 120 after the injury. The horse started to compete in international eventing three months later, once again reaching a similar standard of performance.

The Use of two Mesenchymal Stem Cell Doses as a Treatment for a Horse with Superficial Digital Flexor Tendinopathy